Research programme: adenosine A2B receptor antagonists - ChemBridge Corporation
Alternative Names: CMB 6446Latest Information Update: 07 Dec 2006
At a glance
- Originator ChemBridge Corporation
- Class
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Asthma
Most Recent Events
- 20 Apr 2001 Preclinical development for Allergic asthma in USA (Unknown route)
- 20 Apr 2001 Preclinical development for Asthma in USA (Unknown route)